Dutton Associates Highlights: Neoprobe Corp. (NEOP.OB) with a “Strong Speculative Buy” Rating; as Company Reports Phase 2 Clinical Trial Results
Neoprobe Corporation (NEOP.OB), a diversified developer of innovative oncology and cardiovascular surgical and diagnostic products, reports positive preliminary results from a multicenter Phase 2 clinical study of its lead clinical candidate, Lymphoseek®. (Technetium Tc99m DTPA-mannosyl-dextran). Lymphoseek is a proprietary radioactive targeting agent being developed for use with handheld gamma detection devices, such as Neoprobe's neo2000® system, in a surgical procedure known as Sentinel Lymph Node Biopsy (SLNB). The primary endpoint of this multicenter, single-arm, open-label, within-patient, single-dose, multi-stage trial measured the rate at which Lymphoseek localized to lymphoid tissue with a goal of achieving 90% localization. In results reported today, localization…
